Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $163.4 million.

  • Catalyst Pharmaceuticals' Income towards Parent Company rose 20.28% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.1 million, marking a year-over-year increase of 65.79%. This contributed to the annual value of $163.4 million for FY2024, which is 174.43% up from last year.
  • According to the latest figures from FY2024, Catalyst Pharmaceuticals' Income towards Parent Company is $163.4 million, which was up 174.43% from $59.5 million recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Income towards Parent Company ranged from a high of $163.4 million in FY2024 and a low of $39.5 million during FY2021.
  • Moreover, its 3-year median value for Income towards Parent Company was $83.1 million (2022), whereas its average is $102.0 million.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Income towards Parent Company tumbled by 47.35% in 2021, and later spiked by 174.43% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Income towards Parent Company (Yearly) stood at $75.0 million in 2020, then plummeted by 47.35% to $39.5 million in 2021, then surged by 110.42% to $83.1 million in 2022, then declined by 28.34% to $59.5 million in 2023, then spiked by 174.43% to $163.4 million in 2024.